Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Freeman

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
European Urology Focus|March 15, 2022
Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell CarcinomasAngela Yoo, Cerise Tang, Mark Zucker, et al.
European Urology Focus|December 10, 2019
Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical CourseRenzo G DiNatale, Alexander N Gorelick, Vladimir Makarov, et al.
Haematologica|January 25, 2024
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignanciesLinlin Xu, Mazyar Shadman, Ian W Flinn, et al.
The Lancet. Haematology|November 18, 2022
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm studyMazyar Shadman, Ian W Flinn, Moshe Y Levy, et al.
European Urology Oncology|August 6, 2024
Clinical Outcomes and Targeted Genomic Analysis of Renal Cell Carcinoma Brain Metastases Treated with Stereotactic RadiosurgeryJennifer Ma, Luke Del Balzo, Henry Walch, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
European Urology Focus|March 15, 2022
Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell CarcinomasAngela Yoo, Cerise Tang, Mark Zucker, et al.
European Urology Focus|December 10, 2019
Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical CourseRenzo G DiNatale, Alexander N Gorelick, Vladimir Makarov, et al.
Haematologica|January 25, 2024
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignanciesLinlin Xu, Mazyar Shadman, Ian W Flinn, et al.
The Lancet. Haematology|November 18, 2022
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm studyMazyar Shadman, Ian W Flinn, Moshe Y Levy, et al.
European Urology Oncology|August 6, 2024
Clinical Outcomes and Targeted Genomic Analysis of Renal Cell Carcinoma Brain Metastases Treated with Stereotactic RadiosurgeryJennifer Ma, Luke Del Balzo, Henry Walch, et al.
Pageof 2